Clinical Report: Characteristics, Management, and Prognosis of Immune Thrombocytopenia Induced by Oxaliplatin
Overview
Oxaliplatin-induced immune thrombocytopenia (OITP) is a rare but serious complication characterized by acute thrombocytopenia following oxaliplatin treatment. This report highlights the clinical features, management strategies, and prognosis of OITP based on a retrospective analysis of 40 patients.
Background
OITP is a type II hypersensitivity reaction that can lead to severe thrombocytopenia, often misidentified as typical myelosuppression. Understanding OITP is crucial as it can result in significant morbidity and mortality, particularly in patients undergoing chemotherapy for colorectal cancer. Awareness and prompt management are essential to mitigate risks associated with this condition.
Data Highlights
Characteristic
Value
Median Age
59 years (range, 36–83 years)
Female Predominance
65.0%
Primary Malignancy
Colorectal Cancer (92.5%)
Median Platelet Count Nadir
6×10^9/L
Recovery Rate
92.5%
Mortality Rate
7.5%
Key Findings
OITP typically occurs after multiple cycles of oxaliplatin, with a median onset after the 9th cycle.
82.5% of patients experienced platelet counts dropping below 25×10^9/L.
65.0% of patients exhibited hemorrhagic symptoms, and 52.5% had systemic hypersensitivity symptoms.
Oxaliplatin was discontinued in all cases, with glucocorticoids and platelet transfusions being the most common management strategies.
The overall recovery rate was 92.5%, with a median recovery time of 7 days.
Clinical Implications
Healthcare providers should maintain a high index of suspicion for OITP in patients receiving oxaliplatin, particularly after prolonged treatment. Immediate cessation of oxaliplatin and initiation of supportive care, including glucocorticoids and platelet transfusions, are critical for managing this condition effectively.
Conclusion
OITP is a significant complication of oxaliplatin therapy that requires prompt recognition and management. Continued vigilance and research are necessary to improve outcomes for affected patients.
